Literature DB >> 15236278

Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach.

Stewart J Kellie1, Hayden Boyce, Ira J Dunkel, Blanca Diez, Marc Rosenblum, Lynette Brualdi, Jonathan L Finlay.   

Abstract

PURPOSE: High rates of overall and event-free survival have been reported in patients with intracranial germinomas treated with craniospinal radiotherapy. More recently, similar results have been reported with chemotherapy combined with radiotherapy to more localized treatment volumes. Our interest in exploring chemotherapy without radiotherapy in patients with CNS germinomas was based on concerns about the late sequelae of radiotherapy to the brain or neuraxis and also the well documented success of chemotherapy alone in patients with disseminated extracranial germinomas. The primary objective of this study was to determine whether intensive cisplatin and cyclophosphamide-based combination chemotherapy, without radiotherapy, was effective in patients with CNS germinomas. PATIENTS AND METHODS: Nineteen patients were enrolled, ranging in age from 1 to 24 years (median, 14 years). Thirteen were male. Nine had diabetes insipidus. Therapy comprised two courses of Regimen 'A' (cisplatin, etoposide, cyclophosphamide, and bleomycin) followed by MRI evaluation. Patients achieving a complete remission (CR) completed all planned therapy with two courses of regimen 'B' (carboplatin, etoposide, and bleomycin). Patients achieving less than a CR received two courses of Regimen 'B' followed by another evaluation. Those in CR after four courses of treatment received one additional course of Regimen 'A' and Regimen 'B', while those not in CR after four treatment courses underwent second look surgery and/or radiation therapy.
RESULTS: Eleven of 11 patients with residual postoperative disease assessable for response achieved a CR. With a median follow-up of 6.5 years, eight out of 19 (0.42) patients remain in CR 1 without radiotherapy and another three patients are in stable second or subsequent remissions. Three patients died from treatment-related toxicity and another died in CR 1 from an uncharacterized leukoencephalopathy. The 5-year event-free survival (EFS) was 0.47 +/- 0.23 and 5-year overall survival (OS) was 0.68 +/- 0.22.
CONCLUSIONS: Intensive cisplatin and cyclophosphamide-based chemotherapy was effective in achieving remissions, however, the long-term outcome using this treatment program was unsatisfactory and associated with unacceptable morbidity and mortality, particularly in patients with diabetes insipidus. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236278     DOI: 10.1002/pbc.20026

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.

Authors:  J Lee Villano; Irim Y Virk; Vanessa Ramirez; Jennifer M Propp; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

2.  Diabetes insipidus in pediatric germinomas of the suprasellar region: characteristic features and significance of the pituitary bright spot.

Authors:  John-Paul Kilday; Suzanne Laughlin; Stacey Urbach; Eric Bouffet; Ute Bartels
Journal:  J Neurooncol       Date:  2014-09-30       Impact factor: 4.130

3.  Treatment and survival of primary intracranial germ cell tumors: a population-based study using SEER database.

Authors:  Steven Denyer; Abhiraj D Bhimani; Shashank N Patil; Andrew Mudreac; Mandana Behbahani; Ankit I Mehta
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-19       Impact factor: 4.553

4.  Lymphocytic hypophysitis with central diabetes insipidus and subsequent hypopituitarism masking a suprasellar germinoma in a 13-year-old girl.

Authors:  Yoko Mikami-Terao; Masaharu Akiyama; Takaaki Yanagisawa; Junko Takahashi-Fujigasaki; Kentaro Yokoi; Kohei Fukuoka; Mio Sakuma; Ichiro Miyata; Kohji Fujisawa; Shizuo Oi; Yoshikatsu Eto
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

5.  Platinum compounds and sodium metabolism in children with diencephalic glioma.

Authors:  N Puma; A Ruggiero; M Scalzone; P Coccia; S Triarico; G Trombatore; S Mastrangelo; R Riccardi
Journal:  J Neurooncol       Date:  2013-07-10       Impact factor: 4.130

6.  Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

Authors:  Jason Fangusaro; Shengjie Wu; Shannon MacDonald; Erin Murphy; Dennis Shaw; Ute Bartels; Soumen Khatua; Mark Souweidane; Hsiao-Ming Lu; David Morris; Ashok Panigrahy; Arzu Onar-Thomas; Maryam Fouladi; Amar Gajjar; Girish Dhall
Journal:  J Clin Oncol       Date:  2019-09-23       Impact factor: 44.544

7.  Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

Authors:  J Lee Villano; Jennifer M Propp; Kimberly R Porter; Andrew K Stewart; Tibor Valyi-Nagy; Xinyu Li; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

8.  Long term outcomes in patients with intracranial germinomas: a single institution experience of irradiation with or without chemotherapy.

Authors:  Yasuhiro Kawabata; Jun A Takahashi; Yoshiki Arakawa; Mitsuaki Shirahata; Nobuo Hashimoto
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

Review 9.  Primary intracranial germ-cell tumors in adults: a practical review.

Authors:  Jacoline E C Bromberg; Brigitta G Baumert; Filip de Vos; Johanna M M Gijtenbeek; Erkan Kurt; Anneke M Westermann; Pieter Wesseling
Journal:  J Neurooncol       Date:  2013-03-23       Impact factor: 4.130

10.  Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation.

Authors:  Sylvia Cheng; John-Paul Kilday; Normand Laperriere; Laura Janzen; James Drake; Eric Bouffet; Ute Bartels
Journal:  J Neurooncol       Date:  2016-01-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.